ReviewCureus2025
Optical Coherence Tomography Angiography in Detecting Subclinical Changes in Glaucoma Suspects: A Scoping Review.
Review in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Optical coherence tomography angiography (OCTA) offers a promising approach for detecting subclinical microvascular changes in glaucoma suspects before structural or functional damage becomes apparent. This scoping review synthesizes evidence from 11 studies (2014-2025) to evaluate OCTA's effectiveness in identifying early glaucomatous alterations. Findings consistently demonstrate reduced vessel density (VD) in glaucoma suspects compared to healthy controls, with whole-image VD averaging 51.3% versus 55.5% (P<0.001), respectively. OCTA-derived parameters, particularly peripapillary and macular VD, showed diagnostic accuracy (area under the receiver-operating characteristic curve (AUROC): 0.70-0.84) comparable to structural OCT metrics like retinal nerve fiber layer thickness. Notably, microvascular asymmetry and deep-layer capillary dropout emerged as early markers, often preceding visual field defects. Longitudinal data revealed faster VD decline in preperimetric glaucoma (-2.23%/year) than in healthy eyes (0.29%/year), highlighting OCTA's potential for monitoring progression. Despite methodological heterogeneity, OCTA complements structural assessments, providing actionable insights for early glaucoma detection. Standardization of protocols and longitudinal validation are needed to optimize clinical utility. These findings support OCTA's role in enhancing risk stratification for glaucoma suspects.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.